Cancer Panel


Tremendous strides have been made in the early detection and management of various types of cancer in recent years. Genetics Center’s CLIA certified, CAP accredited, and Children’s Oncology Group (COG) approved laboratories offer the following services to assist you in the care and treatment of your patients with cancer. Genetics Center’s Cancer Panel includes testing for genes which are known to be associated with specific hereditary cancer conditions. In addition, analysis of a cancer specimen involves far more than simply reporting the laboratory results. Our team of medical geneticists, scientists, and genetic counselors provide unparalleled assistance to our referring physicians in the interpretation of abnormalities.



  • Individual with suspected hereditary cancer syndrome or positive family history.
  • Individual with a bilateral or multifocal cancer.
  • Identification of at-risk family members.

Testing for genes can be ordered individually or in custom-designed panels. Genetics Center’s Cancer Panel can test for any of the following conditions:

  • Ataxia Telangiectasia (ATM)
  • Bannayan-Riley-Ruvalcaba syndrome (PTEN)
  • Birt-Hogg-Dube syndrome (FLCN)
  • Bloom syndrome (BLM)
  • CHEK2-related cancer (CHEK2)
  • Cowden syndrome (PTEN)
  • Comprehensive Colon Cancer Panel
    • Includes Lynch syndrome, APC, MUTYH, PTEN, SMAD4, BMPR1A, STK11, TP53
  • Congenital Central Hypoventilation syndrome (PHOX2B)
  • Costello syndrome (HRAS)
  • Denys-Drash syndrome (WT1)
  • Familial adenomatous polyposis (APC)
  • Familial cutaneous malignant melanoma (CDH1)
  • Familial Medullary Thyroid Carcinoma (RET)
  • Fanconi Anemia (contact us for complementation group list)
  • Fumarate hydratase deficiency (FH)
  • Gardner syndrome (APC)
  • Gorlin syndrome (PTCH1)
  • Hereditary Breast and Ovarian Cancer Syndrome (BRCA1,BRCA2)
  • Hereditary diffuse gastric cancer (CDH1)
  • JAK2-related disorders (JAK2)
  • Juvenile Polyposis syndrome (BMPR1A, SMAD4)
  • Li-Fraumeni syndrome (TP53)
  • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM and MUTYH)
  • Multiple Endocrine Neoplasia, Type 1 (MEN1)
  • Multiple Endocrine Neoplasia, Types 2A & 2B (RET)
  • Neurofibromatosis, Type 2 (NF2)
  • Nijmegen Breakage Syndrome (NBN)
  • PALB2-related cancer (PALB2)
  • Peutz-Jeghers syndrome (STK11)
  • PTEN Hamartoma Tumor Syndrome (PTEN)
  • Polyposis Syndrome Comprehensive Panel (APC, MUTYH)
    • Includes FAP, Gardner syndrome, Turcot syndrome and attenuated FAP
  • Schwachman-Diamond syndrome (SBDS)
  • Schwannomatosis (SMARCB1)
  • Simpson-Golabi-Behmel syndrome (GPC3)
  • Sotos syndrome (NSD1)
  • Tuberous sclerosis (TSC1 & TSC2)
  • Turcot syndrome (APC)
  • Von Hippel Lindau (VHL)
  • Werner syndrome (WRN)
  • Wilms tumor (WT1)

Cytogenetic Panels:

  • Cytogenetics – Karyotyping only: metaphase analysis of chromosome abnormalities for detection of chromosomal gains and/or losses, translocations, and inversions that are specific to hematopoietic malignancies. Chromosome analysis on solid tumors is available as well.
  • Cytogenetics with Reflex to Fluorescence in situ Hybridization (FISH): metaphase analysis of chromosome abnormalities for detection of chromosomal gains and/or losses, translocations, and inversions that are specific to hematopoietic malignancies. Further reflex to FISH for chromosome locus specific study as indicated. Chromosome & FISH analysis on solid tumors is available as well.
  • Fluorescence in situ hybridization (FISH) for Leukemias and Myeloid Disorders: the following profiles and more are available:
    • Chronic myelogenic leukemia
    • Chronic lymphocytic leukemia
    • Myelodysplasitc syndrome
    • Multiple myeloma
    • Non-Hodgkin lymphoma
    • T-cell lymphoma
    • B-cell acute lymphoblastic leukemia
    • T-cell acute lymphoblastic leukemia
    • Acute myeloid leukemia

Molecular Genetic Tumor Testing:

  • Colorectal Cancer Mutation Screening: examines select exons of KRAS (exons 1 and 2) and BRAF (exons 11 and 15) for known pathogenic activating mutations by gene sequencing in tumor tissue. Molecular testing for both BRAF and KRAS mutations is recommended for all colorectal cancer patients to ensure the best treatment strategies, and to determine if patients are likely to respond to anti-EGFR therapies.
  • BRAF and/or KRAS Mutation Analysis for other common tumors (eg. pancreatic, endometrial, gastric, thyroid, and many others is also available upon request).


  • Testing is performed by Next Generation Sequencing and Deletion/Duplication Analysis. Certain results may be verified by other molecular methods.


  • 14 days


  • Blood: A single tube with 1-5 mL whole blood in EDTA (lavender top).
  • Saliva: Please contact us for collection kit.


  • Shipping: Store blood at 4°C until shipment. Ship at ambient temperature in an insulated container via overnight delivery within 96 hours of collection.
  • Send to:
    Genetics Center
    211 S. Main Street
    Suite AA
    Orange, CA 92868
    Tel: (714)288-3500




    Gene Sequencing Analysis and Deletion/Duplication is unable to detect mutation or deletions in regions of the gene not examined, which may include promoter regions, introns, and additional exons unless otherwise specified. It is possible that some patients may carry a rare mutation of this nature not detected by this assay. This assay may detect polymorphisms of unknown clinical significance, which may require further studies.



    Please contact Genetics Center at (714)288-3500 x314 for more information.